|
Match
|
Document |
Document Title |
|
|
US20090298785 |
Method for Treating Ocular Cancer
It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53...
|
|
|
US20090298743 |
HYDROPHOBIC COMPOSITIONS CONTAINING RECONSTITUTION ENHANCER
Disclosed are compositions comprising a hydrophobic active agent, a polymer and a reconstitution enhancing agent. Reconstitution of the lyophilized form of the compositions takes less time than in...
|
|
|
US20090297506 |
Classification of cancer
The invention discloses a method for classification of cancer in an individual having contracted cancer. The method of classification involves the determination of microsatellite status and a...
|
|
|
US20090291049 |
Targeted delivery to human diseases and disorders
The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target...
|
|
|
US20090285878 |
Compositions and methods for stabilizing liposomal drug formulations
The present invention is directed to liposomal compositions comprising a camptothecin, which are optimized to reduce camptothecin degradation and/or precipitation of camptothecin degradation...
|
|
|
US20090275603 |
NF- kB Inhibitors And Uses Thereof
A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent...
|
|
|
US20090274762 |
REHYDRATABLE PHARMACEUTICAL PRODUCT
A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged...
|
|
|
US20090274698 |
Combination anti-cancer therapy
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective...
|
|
|
US20090269281 |
Calcium/Calmodulin-Dependent Protein Kinase Kinase as a Control Point for Cardiac Hypertrophy
The present invention includes compositions and methods for treating a patient with cardiac hypertrophy by providing the patient with an effective amount of a Calmodulin kinase kinase inhibitor...
|
|
|
US20090263397 |
Combination anti-cancer therapy
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective...
|
|
|
US20090258071 |
COMPOSITIONS AND METHODS FOR PH TARGETED DRUG DELIVERY
The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock...
|
|
|
US20090247564 |
Crystalline Form of Vinflunine Ditartrate
The present invention relates to a novel crystalline form of vinflunine, to a process for preparing it, and to its uses in the therapeutic field, in particular for treating cancer.
|
|
|
US20090247563 |
Novel Processes for the Production of Useful Intermediates
The present application relates to a new process for the asymmetric production of 3-(pyridin-4-yl)-3-hydroxy-pentanoic acid derivatives, which are useful intermediates in the manufacture of...
|
|
|
US20090247475 |
METHODS AND COMPOSITIONS RELATING TO PHARMACOGENETICS OF DIFFERENT GENE VARIANTS IN THE CONTEXT OF IRINOTECAN-BASED THERAPIES
The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these...
|
|
|
US20090239893 |
STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN
A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps...
|
|
|
US20090232827 |
Compositions and methods of use of compounds to increase cancer patient survival time
The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses...
|
|
|
US20090227617 |
Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy
The invention relates to novel esters and in particular to some novel esters of glucuronide prodrugs of anthracyclines having tunable water-solubility, their synthesis and use in tumor-selective...
|
|
|
US20090227616 |
INHIBITORS OF AKT ACTIVITY
Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
|
|
|
US20090221622 |
TOPOTECAN READY TO USE SOLUTIONS
Aqueous-based, ready to use topotecan-containing formulations for parenteral use having extended stability are disclosed. The formulations are surprisingly free of precipitated degradation products...
|
|
|
US20090221609 |
Gene Predictors of Response to Metastatic Colorectal Chemotherapy
The present invention provides for the identification of genes that are expressed in tumors that are responsive to a given therapeutic regime and whose expression correlates with responsiveness to...
|
|
|
US20090216317 |
Delivery of Highly Lipophilic Agents Via Medical Devices
An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the...
|
|
|
US20090214529 |
KINESIN INHIBITORS
This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated...
|
|
|
US20090214508 |
VEGF-ACTIVATED FAS LIGANDS
The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells...
|
|
|
US20090214435 |
Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof
A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and...
|
|
|
US20090209494 |
21-DEOXYMACBECIN ANALOGUES USEFUL AS ANTITUMOR AGENTS
The present invention relates to 21-deoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system...
|
|
|
US20090203632 |
COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE
A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture....
|
|
|
US20090197821 |
COMPOSITIONS AND METHODS FOR THE DELIVERY OF POORLY WATER SOLUBLE DRUGS AND METHODS OF TREATMENT
The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water-soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5...
|
|
|
US20090196918 |
Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
Provided is a liposome comprising a hydrophobic lactone drug and a cyclodextrin, wherein the liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the...
|
|
|
US20090192184 |
Crystalline Polymorphs of Topotecan Hydrochloride and Methods for the Preparation Thereof
The invention relates to two novel crystalline form of Topotecan hydrochloride (Ia)
Herein referred to as forms α and β, characterized by high purity and whose preparation is advantageous from...
|
|
|
US20090191152 |
INTRALYMPHATIC CHEMOTHERAPY DRUG CARRIERS
A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not...
|
|
|
US20090180986 |
TREATING UNWANTED OCULAR CONDITIONS USING AN ASCOMYCIN MACROLACTAM
The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically...
|
|
|
US20090175869 |
Pulsatile Dosing of Gossypol for Treatment of Disease
This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to...
|
|
|
US20090169601 |
Transdermal Therapeutic System for Administering Lipophilic and/or Sparingly Skin- Permeable Active Substances
A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a...
|
|
|
US20090162440 |
SODIUM ALGINATE MICROSPHERE VASCULAR EMBOLUS CONTAINING WATER-SOLUBLE DRUG AND PREPARATION AND APPLICATION THEREOF
The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into...
|
|
|
US20090162288 |
Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject...
|
|
|
US20090156629 |
INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES
The present invention provides releasably-linked indenoisoquinoline polymer conjugates. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.
|
|
|
US20090149397 |
TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS
In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the...
|
|
|
US20090142332 |
Identification of Biomarkers by Serum Protein Profiling
The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The...
|
|
|
US20090131529 |
TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS
In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP...
|
|
|
US20090130228 |
PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer...
|
|
|
US20090130163 |
Drugs With Improved Hydrophobicity For Incorporation in Medical Devices
The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a...
|
|
|
US20090118271 |
Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a...
|
|
|
US20090118205 |
Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and uses Thereof in the Treatment of Cancer
The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more...
|
|
|
US20090118171 |
Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
The invention relates to the use of enzymatic inhibitors of h-PRUNE and to screening method for the prevention and treatment of the metastases of tumours overexpressing h-PRUNE thereof and to the...
|
|
|
US20090111836 |
Angular Pyranocoumarins, Process for Preparation and Uses Thereof
The present invention relates to compounds, compositions for use in reversing multidrug resistance in cancer cells, process for the preparation thereof and their uses in treating cancers. More...
|
|
|
US20090110717 |
TRANSMUCOSAL COMPOSITION
The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (...
|
|
|
US20090105167 |
Predicting responsiveness to cancer therapeutics
The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides...
|
|
|
US20090105128 |
CANNABINOID RECEPTOR TARGETED AGENT
Compounds of the following formula:
wherein X is H or substituted with
with at least one X being substituted; and halo is fluorine, chlorine, bromine, iodine; and stereoisomers and conjugable...
|
|
|
US20090104254 |
Controlled Release Hydrogels
Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.
|
|
|
US20090104119 |
Dendrimer Based Compositions And Methods Of Using The Same
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based multifunctional compositions and systems for use in...
|